Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

October 15, 2025

Study Completion Date

December 27, 2026

Conditions
Prostatic Neoplasms
Interventions
DRUG

CC-94676

Specified dose on specified days

DRUG

CC1083611

Specified dose on specified days

DRUG

CC1083610

Specified dose on specified days

Trial Locations (19)

10029

Local Institution - 112, New York

10032

Local Institution - 109, New York

10065

Local Institution - 105, New York

18103

Local Institution - 120, Allentown

19104

Local Institution - 113, Philadelphia

20010

Local Institution - 122, Washington D.C.

21287

Local Institution - 108, Baltimore

27710

Local Institution - 106, Durham

31792

Local Institution - 121, Thomasville

34232

Local Institution - 103, Sarasota

48109

Local Institution - 117, Ann Arbor

49546

Local Institution - 102, Grand Rapids

53792

Local Institution - 111, Madison

75235

Local Institution - 107, Dallas

77030

Local Institution - 119, Houston

78229

Local Institution - 101, San Antonio

98109

Local Institution - 115, Seattle

94305-5826

Local Institution - 116, Stanford

02215

Local Institution - 104, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY